Testing a new medication combined with chemotherapy for advanced cervical cancer

Plain-English translation of NCT05798819 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated October 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new medication called combined with standard chemotherapy drugs to see if it can help treat cervical cancer that has come back or spread to other parts of the body. Half of the participants will receive the medication plus chemotherapy, while the other half will receive a placebo (dummy pill) plus the same chemotherapy. Doctors want to know if adding this medication makes the chemotherapy work better and is safe to use.

Cervical cancer that returns or spreads is difficult to treat, and doctors need better treatment options. This medication works by helping your immune system fight cancer cells, so researchers believe combining it with chemotherapy could improve outcomes for patients.

Do you qualify?

You likely qualify if…

you are a woman between 18 and 75 years old
you have been diagnosed with persistent, recurrent, or metastatic cervical cancer (squamous cell, adenocarcinoma, or adenosquamous types)
your cancer has a specific marker called PD-L1
you have not received chemotherapy for this advanced cancer before
you are in good enough health to tolerate treatment (as measured by your doctor's assessment)
you are willing to use effective birth control for at least 6 months after treatment ends

You likely don't qualify if…

you could be cured by surgery or radiation therapy alone
you have received chemotherapy, radiation, or other treatments for this cancer within the past 4 weeks
your cancer has spread to your brain or central nervous system
you have an active infection or serious autoimmune disease
you are pregnant, breastfeeding, or planning to become pregnant during the trial

What participation looks like

You will be randomly assigned to receive either the new medication or a placebo, both combined with standard chemotherapy drugs ( or plus ). You will continue treatment until your cancer responds, stops responding, or side effects become too serious. Throughout the trial, you will have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and check for any side effects.

AI-generated summary from trial data · Oct 12, 2026 · Not medical advice

Trial locations(1 site)

China

Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai Municipality